The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.